Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?

被引：0
|
作者：
Brown, K. K. [1 ]
Walsh, S. L. F. [2 ]
Devaraj, A. [3 ]
Song, J. [4 ]
Wuyts, W. A. [5 ]
Valenzuela, C. [6 ]
Goeldner, R. [7 ]
Stowasser, S. [8 ]
Schlenker-Herceg, R. [9 ]
Wells, A. U. [2 ,10 ]
机构：
[1] Natl Jewish Hlth, Pulm Crit Care & Sleep Med, Denver, CO USA
[2] Imperial Coll, Natl Heart & Lung Inst, London, England
[3] Royal Brompton & Harefield NHS Fdn Trust, Dept Radiol, London, England
[4] Univ Ulsan, Asan Med Ctr, Pulm & Crit Care Med, Coll Med, Seoul, South Korea
[5] Univ Hosp Leuven, Dept Resp Med, Unit Interstitial Lung Dis, Leuven, Belgium
[6] Hosp Univ La Princesa, Madrid, Spain
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[9] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[10] Royal Brompton & Harefield NHS Fdn, Natl Inst Hlth Res Resp Biomed Res Unit, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1507
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Vincent Cottin
    Fernando J. Martinez
    R. Gisli Jenkins
    John A. Belperio
    Hideya Kitamura
    Maria Molina-Molina
    Inga Tschoepe
    Carl Coeck
    Dirk Lievens
    Ulrich Costabel
    Respiratory Research, 23
  • [32] EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL
    Shapera, Shane
    Moua, Teng
    Nambiar, Anoop
    Morrison, Lake
    Kolb, Martin
    Schlenker-Herceg, Rozsa
    Conoscenti, Craig
    Goeldner, Rainer-Georg
    Rohr, Klaus
    Stowasser, Susanne
    Brown, Kevin
    CHEST, 2020, 158 (04) : 2613A - 2615A
  • [33] Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
    Matteson, Eric L.
    Kelly, Clive
    Distler, Joerg H. W.
    Hoffmann-Vold, Anna-Maria
    Seibold, James R.
    Mittoo, Shikha
    Dellaripa, Paul F.
    Aringer, Martin
    Pope, Janet
    Distler, Oliver
    James, Alexandra
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin R.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (06) : 1039 - 1047
  • [34] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Cottin, Vincent
    Martinez, Fernando J.
    Jenkins, R. Gisli
    Belperio, John A.
    Kitamura, Hideya
    Molina-Molina, Maria
    Tschoepe, Inga
    Coeck, Carl
    Lievens, Dirk
    Costabel, Ulrich
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [35] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases
    Bonella, F.
    Matteson, E.
    Kelly, C.
    Distler, J. H. W.
    Hoffmann-Vold, A.
    Seibold, J. R.
    Mittoo, S.
    Distler, O.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Stowasser, S.
    Quaresma, M.
    Flaherty, K. R.
    PNEUMOLOGIE, 2020, 74 : S61 - S62
  • [36] BEYOND CLINICALTRIALS: EFFICACY AND SAFETY OF NINTEDANIB IN IPF AND PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES IN CLINICAL PRACTICE
    De Gracia, A. I.
    Bea, C.
    Fuertes, E.
    De Castro, A.
    Navarro, L.
    Prades, C.
    Ruiz, D.
    Albiol, P.
    Forner, M. J.
    Vela-Bernal, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1662 - 1663
  • [37] Effect of Genetic Background on Manifestation of Progressive Fibrosing Interstitial Lung Diseases
    Sterclova, M.
    Sikorova, K.
    Kishore, A.
    Petrek, M.
    Vasakova, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [38] Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
    Cottin, Vincent
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153):
  • [39] The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial
    Inoue, Yoshikazu
    Kitamura, Hideya
    Okamoto, Masaki
    Ogura, Takashi
    Nishioka, Yasuhiko
    Kuwana, Masataka
    Taniguchi, Atsushi
    Ito, Tomohiro
    Rohr, Klaus B.
    Suda, Takafumi
    RESPIRATORY INVESTIGATION, 2024, 62 (04) : 589 - 596
  • [40] Nintedanib in chronic fibrosing interstitial lung diseases. A case series
    Sevila, Raquel Garcia
    Jimenez, Juan Jose Arenas
    Casasempere, Paloma Vela
    Perez, Ester Nofuentes
    Garcia-Manso, Ignacio Gaya
    HELIYON, 2024, 10 (07)
12345